- Report
- April 2024
- 80 Pages
Ireland
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
Japan
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
Poland
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
Russia
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
Saudi Arabia
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
South Korea
From €1424EUR$1,500USD£1,201GBP
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
United Kingdom
From €1424EUR$1,500USD£1,201GBP
- Report
- April 2024
- 80 Pages
Vietnam
From €1424EUR$1,500USD£1,201GBP
- Report
- October 2024
- 101 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- July 2023
- 96 Pages
Global
From €3500EUR$3,949USD£3,056GBP
- Report
- February 2022
- 111 Pages
Global
From €3200EUR$3,611USD£2,794GBP
- Report
- October 2023
- 146 Pages
Global
From €3349EUR$3,528USD£2,825GBP
€3940EUR$4,150USD£3,323GBP
- Report
- December 2021
- 255 Pages
Global
From €3524EUR$3,712USD£2,972GBP
- Book
- July 2015
- 384 Pages

The Pulmonary Drug market is a subset of the larger Respiratory Drug market, which includes treatments for a variety of respiratory diseases and conditions. Pulmonary Drugs are used to treat diseases and conditions of the lungs, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and pulmonary hypertension. These drugs are typically inhaled, and can include bronchodilators, corticosteroids, and antibiotics. In addition, Pulmonary Drugs can also be used to treat other respiratory conditions, such as sleep apnea and snoring.
The Pulmonary Drug market is highly competitive, with many companies offering a variety of treatments. Some of the major players in the market include GlaxoSmithKline, Merck & Co., Novartis, Pfizer, and AstraZeneca. Other companies, such as Boehringer Ingelheim, Cipla, and Sun Pharmaceuticals, also offer Pulmonary Drugs. Show Less Read more